FDA Decision Signals New Competition For Some Of The Costliest Drugs

March 10, 2015 9:42 PM

13 0

Mark McCamish spent more than five years preparing for a presentation he gave this winter.

McCamish is in charge of biopharmaceutical drug development at the Sandoz division of Switzerland's Novartis. He and his colleagues made the case to a panel of 14 cancer specialists and a group of Food and Drug Administration regulators that a company drug codenamed EP2006 should be approved for sal...

Read more

To category page